Company intelligence / Profile preview
Zhejiang Zhida Pharmaceutical
Shaoxing, Zhejiang, Chinazhidapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Doxorubicin hydrochloride liposome injection approved and commercialized with approx. $14.5M sales in first six months of launch in China. Irinotecan liposome expected to launch Q4 2025. Option/license agreement signed for Apealea® with Vivesto AB targeting ovarian cancer.
- Therapeutic areas
- Oncology
- Modalities
- Nanoliposome drug deliveryAlbumin nanoparticle drug deliveryPeptide nano drug deliveryHigh-efficiency in vivo nucleic acid drug delivery platformSmall molecule (for doxorubicin, irinotecan)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Vivesto AB – option/license agreement for Apealea® commercialization rights in Greater China region
Beyond the preview
Go deeper on Zhejiang Zhida Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Zhida Pharmaceutical.